Amlodipine/benazepril
 | |
 | |
| Combination of | |
|---|---|
| Amlodipine | Calcium channel blocker |
| Benazepril | ACE inhibitor |
| Clinical data | |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
  (what is this?) (verify) | |
Amlodipine/benazepril, marketed in the U.S. as Lotrel by Novartis and manufactured as a generic drug by Teva and Sandoz, is an antihypertensive medication which combines a calcium channel blocker (amlodipine besilate) with an angiotensin converting enzyme inhibitor (benazepril).[1] This drug, like similar combinations, is prescribed when either agent alone is not sufficient to bring a person's blood pressure down to target range. As a combination agent, Lotrel shares the adverse reaction profile of both of its individual parts.[2][3]
See also
References
External links
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |